EVÄVAARA-DESIGN
11.5.2021 12:48:07 CEST | Business Wire | Press release
Remote working has raised a number of challenges that have been taken up by Finnish pioneering designer of functional furniture, Evävaara Design. Evävaara is launching two completely new workstation designs to fit any home: the larger, mobile sshhh 3 and the smaller sshhh 7 . The workstations support the wellbeing of employees with good ergonomic and acoustic design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005612/en/
Antti Evävaara, founder and chief designer of Evävaara Design, has almost twenty years’ experience in designing and producing functional furniture, with solid expertise in good acoustics and user comfort, which provide the basis for their workstation design.
“In today’s world we are constantly surrounded by irritants and noise that can make it hard to focus on something. Our products aim to create a quiet, personal space that allows you to focus”, says Evävaara .
The furniture-shaped workstations designed by Evävaara are a response to the challenges posed by the increase in remote working. According to remote work and virtual leadership expert Ulla Vikman of Timanttia Consulting, those who do a great deal of remote work, often experience interruptions and are sometimes challenged by a blurred line between work and free time.
“Someone who does a great deal of remote work would be distracted if the necessary tools, such as displays and paperwork, are constantly on all over their home. By intruding your thoughts constantly, these things tend to increase stress levels and focusing becomes more difficult”, says Vikman .
The design of Evävaara workstations is focused on a number of details that support concentration and ergonomics. The wood and felt of the workstation muffles both external and internal noise and improves the acoustics of the whole room. Standard equipment for the workstation includes
- Power sockets and cords
- USB port
- LED lights
- Storage pockets for paperwork and other materials
The larger sshhh3 can be purchased with an additional, adjustable chair. After work, the workstation doors are simply closed and the workstation becomes a mobile cabinet. A neutral colour scheme makes the unit blend seamlessly in any home environment.
In order to boost the efficiency of your working day, Evävaara Design workstations are easy to deploy. The workstation is delivered assembled and ready to use. Evävaara Design workstations are available direct from the designer.
Today the products of Evävaara Design are in use all over Europe wherever a calm space is required, for instance in open plan offices and libraries. They have also garnered some international interest since Vincent Gregoire, Nelly Rodi’s creative director and a celebrity in the business, included Evävaara products in a video showcasing new trends at the Maison & Objet fair in February.
More information: https://www.evavaaradesign.com/etatyopisteet/
Evavaara Design is a Finnish pioneer in functional furniture design in Europe – creating quiet corners for every environment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005612/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
